Colette DeJong

Dr. Colette DeJong is a Clinical Instructor (Affiliated) in the Department of Medicine - Cardiovascular Medicine at Stanford University and a staff member at the Stanford Prevention Research Center. She holds board certifications in Adult Echocardiography, Cardiovascular Disease, and Internal Medicine. Her research focuses on improving access to cardiovascular therapies through innovative strategies like polypills, with a particular emphasis on heart failure management. She led the COMBO-HF-X pilot trial evaluating polypills for heart failure in safety-net systems. Dr. DeJong’s work bridges clinical practice and health policy, addressing adherence challenges and healthcare equity. She is affiliated with the VA Palo Alto and serves on the Board of Trustees for the UCSF Gold-Headed Cane Society.

Education

• Bachelor’s degree from Brown University
• M.D. from University of California, San Francisco (UCSF) School of Medicine (2017)
• Internal Medicine Residency and Chief Residency at UCSF (2021)
• Fellowship in Cardiovascular Medicine at UCSF (2024)
• Editorial Fellowship at JAMA Internal Medicine
• Research Fellowship at UCSF Center for Healthcare Value

Research Interests

Dr. DeJong’s work centers on optimizing cardiovascular care delivery through:

• Development of polypills to simplify heart failure therapy
• Evaluating implementation barriers in guideline-directed medical therapy
• Assessing impacts of healthcare policies (e.g., Inflation Reduction Act) on medication accessibility
• Exploring physician behavior and industry marketing influences on prescribing practices

Awards & Recognition

• ACC/ABC Merck Research Fellowship Award (2023)
• Housestaff Teaching Award (2022)
• Daniel Ford Award for health services research (2018)

Grants & Funding

Her research has been supported by grants for trials like COMBO-HF-X and mixed-methods studies on polypill acceptability. Specific funding sources are not explicitly listed in the provided text.

Labs & Collaborations

Collaborates with the UCSF Center for Healthcare Value, Stanford Prevention Research Center, and institutions like Washington University in St. Louis on polypill research and health policy projects.